Latest News
Tolero and Boston Biomedical Merge to Create Sumitomo Dainippon Pharma Oncology
Monday 06 July 2020

Sumitomo Dainippon Pharma, Inc. subsidiaries, Tolero Pharmaceuticals, Inc. and Boston Biomedical, Inc., two US clinical-stage companies developing novel cancer therapeutics, have merged to form Sumitomo Dainippon Pharma Oncology to advance therapies for patients with cancer, the company said.

Terms of the transaction were not disclosed. This US entity, together with the oncology research and development teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology.

Consolidation of the US companies will combine both organisations' passion, resources and expertise to advance science and research with the goal of bringing cancer therapies to market more rapidly.

Through scientific persistence and a commitment to discovery, SDP Oncology is focussed on advancing a diverse and purposeful pipeline that aims to positively impact outcomes for patients with cancer.

The company's areas of concentration will address unmet needs in oncology and encompass discovery research, external innovation, clinical development and commercialisation.
Date Published: 06/07/2020